Clinical trial · no report yet · Phase 3
NCT06520345
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
- NCT06520345 ↗
- Recruiting
- Telix Pharmaceuticals (Innovations) Pty Limited
- 18 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 9 | |
| YouTube | 7 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- 177Lu-TLX591; Enzalutamide; Abiraterone; Docetaxel
- Arms
- 177Lu-TLX591 + Enzalutamide or Abiraterone or Docetaxel · Experimental
- Control Arm (Enzalutamide or Abiraterone or Docetaxel) · Active comparator
- Enrollment
- 520 (estimated)
- Primary outcomes
- Radiographic Progression-free Survival
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Start
- Jul 26, 2024
- Primary completion
- Dec 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06520345 · updated Jul 21, 2026